25 results on '"Ndao, Momar"'
Search Results
2. Malaria 'epidemic' in Quebec: diagnosis and response to imported malaria
- Author
-
Ndao, Momar, Bandyayera, Etienne, Kokoskin, Evelyne, Diemert, David, Gyorkos, Theresa W., MacLean, J. Dick, St. John, Ron, and Ward, Brian J.
- Subjects
Medical care surveys -- Analysis ,Refugees, African -- Health aspects ,Refugees, African -- Surveys ,Malaria -- Development and progression - Abstract
Abstract Background: Imported malaria is an increasing problem. The arrival of 224 African refugees presented the opportunity to investigate the diagnosis and management of imported malaria within the Quebec health [...]
- Published
- 2005
3. Prevalence and distribution of schistosomiasis in human, livestock, and snail populations in northern Senegal: a One Health epidemiological study of a multi-host system
- Author
-
Léger, Elsa, Borlase, Anna, Fall, Cheikh B, Diouf, Nicolas D, Diop, Samba D, Yasenev, Lucy, Catalano, Stefano, Thiam, Cheikh T, Ndiaye, Alassane, Emery, Aidan, Morrell, Alice, Rabone, Muriel, Ndao, Momar, Faye, Babacar, Rollinson, David, Rudge, James W, Sène, Mariama, and Webster, Joanne P
- Abstract
Schistosomiasis is a neglected tropical disease of global medical and veterinary importance. As efforts to eliminate schistosomiasis as a public health problem and interrupt transmission gather momentum, the potential zoonotic risk posed by livestock Schistosomaspecies via viable hybridisation in sub-Saharan Africa have been largely overlooked. We aimed to investigate the prevalence, distribution, and multi-host, multiparasite transmission cycle of Haematobiumgroup schistosomiasis in Senegal, West Africa.
- Published
- 2020
- Full Text
- View/download PDF
4. Characterization and Diagnostic Application of Trypanosoma cruziTrypomastigote Excreted-Secreted Antigens Shed in Extracellular Vesicles Released from Infected Mammalian Cells
- Author
-
Bautista-López, Norma L., Ndao, Momar, Camargo, Fabio Vasquez, Nara, Takeshi, Annoura, Takeshi, Hardie, Darryl B., Borchers, Christoph H., and Jardim, Armando
- Published
- 2017
- Full Text
- View/download PDF
5. Still hope for schistosomiasis vaccine
- Author
-
Ricciardi, Alessandra and Ndao, Momar
- Abstract
Schistosomiasis is a parasitic disease caused by helminths belonging to the Schistosoma genus. Approximately 700 million people are at risk of infection and 200 million people are currently infected. Schistosomiasis is the most important helminth infection, and treatment relies solely on the drug praziquantel. Worries of praziquantel resistance as well as high disease burden are only some of the justifications which support the development of a vaccine against schistosomiasis. To date, only 2 schistosome vaccines have made it into clinical trials: Sh28GST (Bilhvax) and Sm14. However, there are several vaccine candidates, such as TSP-2, sm-p8, and Sm-Cathepsin B, which are generating promising results in pre-clinical studies. Schistosomiasis vaccine development has been an uphill battle, and there are still several hurdles to overcome in the future. Fortunately, the research groups involved in the research for vaccine development have not abandoned their work. Furthermore, in the last few years, schistosomiasis has garnered some additional attention on a global scale due to its significant impact on public health.
- Published
- 2015
- Full Text
- View/download PDF
6. Diagnosis of Parasitic Infections: What’s Going On?
- Author
-
Ricciardi, Alessandra and Ndao, Momar
- Abstract
Methods for the diagnosis of parasitic infections have stagnated in the past three decades. Labor-intensive methods such as microscopy still remain the mainstay of several diagnostic laboratories. There is a need for more rapid tests that do not sacrifice sensitivity and that can be used in both clinical settings as well as in poor resource field settings. The fields of diagnostic medical parasitology, treatment, and vaccines are undergoing dramatic change. In recent years, there has been tremendous effort to focus research on the development of newer diagnostic methods focusing on serological, molecular, and proteomic approaches. This article examines the various diagnostic tools that are being used in clinical laboratories, optimized in reference laboratories, and employed in mass screening programs.
- Published
- 2015
- Full Text
- View/download PDF
7. Apolipoprotein A-I Truncations in Chagas Disease Are Caused by Cruzipain, the Major Cysteine Protease of Trypanosoma cruzi
- Author
-
Miao, Qianqian, Santamaria, Cynthia, Bailey, Dana, Genest, Jacques, Ward, Brian J., and Ndao, Momar
- Abstract
Trypanosoma cruziis the etiologic agent of Chagas disease. Approximately 10 million people are infected worldwide. We have previously reported that in individuals infected with T. cruzi, apolipoprotein A-I (Apo A-I), the major structural component of host high-density lipoprotein, was truncated into fragments that are specific to Chagas disease and have the potential to be used as diagnostic biomarkers. We investigated the possibility that cruzipain, the major cysteine protease of T. cruzi, is responsible for truncating host Apo A-I. We found that due to Apo A-I truncation, the high-density lipoprotein subspecies profile is altered in individuals with Chagas disease compared with healthy controls. Western blot analysis revealed that both purified Apo A-I protein and Apo A-I in the high-density lipoprotein complex were susceptible to cruzipain cleavage, and the sizes of the truncation product in the latter matched the sizes of Apo A-I biomarkers. We also found that in vitrofeeding T. cruzi–infected differentiated human adipocytes with purified human high-density lipoprotein led to the appearance of the biomarker fragments of Apo A-I. Cruzipain is found both on the cytoplasmic membrane and in the internal lysosomal structure of T. cruzi.We demonstrate that cruzipain from both sources contributes to the production of Apo A-I truncation in the biomarker set.
- Published
- 2014
- Full Text
- View/download PDF
8. Reversible Cysteine Protease Inhibitors Show Promise for a Chagas Disease Cure
- Author
-
Ndao, Momar, Beaulieu, Christian, Black, W. Cameron, Isabel, Elise, Vasquez-Camargo, Fabio, Nath-Chowdhury, Milli, Massé, Frédéric, Mellon, Christophe, Methot, Nathalie, and Nicoll-Griffith, Deborah A.
- Abstract
ABSTRACTThe cysteine protease cruzipain is essential for the viability, infectivity, and virulence of Trypanosoma cruzi, the causative agent of Chagas disease. Thus, inhibitors of cruzipain are considered promising anti-T. cruzichemotherapeutic agents. Reversible cruzipain inhibitors containing a nitrile “warhead” were prepared and demonstrated 50% inhibitory concentrations (IC50s) as potent as 1 nM in baculovirus-generated cruzipain enzyme assays. In epimastigote and intracellular amastigote in vitroassays, the most potent compounds demonstrated antiparasitic behavior in the 5 to 10 μM IC50range; however, trypomastigote production from the amastigote form was ∼90 to 95% inhibited at 2 μM. Two key compounds, Cz007 and Cz008, with IC50s of 1.1 and 1.8 nM, respectively, against the recombinant enzyme were tested in a murine model of acute T. cruziinfection, with oral dosing in chow for 28 days at doses from 3 to 50 mg/kg of body weight. At 3 mg/kg of Cz007 and 3 mg/kg of Cz008, the blood parasitemia areas under the concentration-time curves were 16% and 25% of the untreated group, respectively. At sacrifice, 24 days after immunosuppression with cyclophosphamide, parasite presence in blood, heart, and esophagus was evaluated. Based on negative quantitative PCR results in all three tissues, cure rates in surviving animals were 90% for Cz007 at 3 mg/kg, 78% for Cz008 at 3 mg/kg, and 71% for benznidazole, the control compound, at 50 mg/kg.
- Published
- 2013
- Full Text
- View/download PDF
9. A Cysteine Protease Inhibitor Rescues Mice from a Lethal Cryptosporidium parvumInfection
- Author
-
Ndao, Momar, Nath-Chowdhury, Milli, Sajid, Mohammed, Marcus, Victoria, Mashiyama, Susan T., Sakanari, Judy, Chow, Eric, Mackey, Zachary, Land, Kirkwood M., Jacobson, Matthew P., Kalyanaraman, Chakrapani, McKerrow, James H., Arrowood, Michael J., and Caffrey, Conor R.
- Abstract
ABSTRACTCryptosporidiosis, caused by the protozoan parasite Cryptosporidium parvum, can stunt infant growth and can be lethal in immunocompromised individuals. The most widely used drugs for treating cryptosporidiosis are nitazoxanide and paromomycin, although both exhibit limited efficacy. To investigate an alternative approach to therapy, we demonstrate that the clan CA cysteine protease inhibitor N-methyl piperazine-Phe-homoPhe-vinylsulfone phenyl (K11777) inhibits C. parvumgrowth in mammalian cell lines in a concentration-dependent manner. Further, using the C57BL/6 gamma interferon receptor knockout (IFN-γR-KO) mouse model, which is highly susceptible to C. parvum, oral or intraperitoneal treatment with K11777 for 10 days rescued mice from otherwise lethal infections. Histologic examination of untreated mice showed intestinal inflammation, villous blunting, and abundant intracellular parasite stages. In contrast, K11777-treated mice (210 mg/kg of body weight/day) showed only minimal inflammation and no epithelial changes. Three putative protease targets (termed cryptopains 1 to 3, or CpaCATL-1, -2, and -3) were identified in the C. parvumgenome, but only two are transcribed in infected mammals. A homology model predicted that K11777 would bind to cryptopain 1. Recombinant enzymatically active cryptopain 1 was successfully targeted by K11777 in a competition assay with a labeled active-site-directed probe. K11777 exhibited no toxicity in vitroand in vivo, and surviving animals remained free of parasites 3 weeks after treatment. The discovery that a cysteine protease inhibitor provides potent anticryptosporidial activity in an animal model of infection encourages the investigation and development of this biocide class as a new, and urgently needed, chemotherapy for cryptosporidiosis.
- Published
- 2013
- Full Text
- View/download PDF
10. Interlaboratory Optimization and Evaluation of a Serological Assay for Diagnosis of Human Baylisascariasis
- Author
-
Rascoe, Lisa N., Santamaria, Cynthia, Handali, Sukwan, Dangoudoubiyam, Sriveny, Kazacos, Kevin R., Wilkins, Patricia P., and Ndao, Momar
- Abstract
ABSTRACTA Western blot assay using a recombinant protein, recombinant Baylisascaris procyonisRAG1 protein (rBpRAG1), was developed for the diagnosis of human baylisascariasis concurrently by the Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia, and the National Reference Centre for Parasitology (NRCP) in Montreal, Canada. Assay performance was assessed by testing 275 specimens at the CDC and 405 specimens at the NRCP. Twenty specimens from 16 cases of baylisascariasis were evaluated. Eighteen were positive, with the assay correctly identifying 14 of 16 patients. The rBpRAG1 Western blot assay showed no cross-reactivity with Toxocara-positive serum and had an overall sensitivity of 88% and a specificity of 98%.
- Published
- 2013
- Full Text
- View/download PDF
11. Reprofiled drug targets ancient protozoans
- Author
-
Debnath, Anjan, Ndao, Momar, and Reed, Sharon L.
- Abstract
Recently, we developed a novel automated, high throughput screening (HTS) methodology for the anaerobic intestinal parasite Entamoeba histolytica.We validated this HTS platform by screening a chemical library containing US Food and Drug Administration (FDA)-approved drugs and bioactive compounds. We identified an FDA-approved drug, auranofin, as most active against E. histolyticaboth in vitro and in vivo. Our cell culture and animal studies indicated that thioredoxin reductase, an enzyme involved in reactive oxygen species detoxification, was the target for auranofin in E. histolytica. Here, we discuss the rationale for drug development for three parasites which are major causes of diarrhea worldwide, E. histolytica, Giardia lambliaand Cryptosporidium parvumand extend our current finding of antiparasitic activity of auranofin to Entamoebacysts, G. lambliaand C. parvum. These studies support the use of HTS assays and reprofiling FDA-approved drugs for new therapy for neglected tropical diseases.
- Published
- 2013
- Full Text
- View/download PDF
12. A study of a self diagnostic platform for the detection of A2 biomarker for Leishmania donovani
- Author
-
Roche, Philip J. R., Cheung, Maurice C., Najih, Mohamed, McCall, Laura-Isobel, Fakih, Ibrahim, Chodavarapu, Vamsy P., Ward, Brian, Ndao, Momar, and Kirk, Andrew G.
- Abstract
Visceral leishmaniasis (L.donovani) is a protozoan infection that attacks mononuclear phagocytes and causes the liver and spleen damage that can cause death. The investigation presented is a proof of concept development applying a plasmonic diagnostic platform with simple microfluidic sample delivery and optical readout. An immune-assay method is applied to the quantification of A2 protein, a highly immunogenic biomarker for the pathogen. Quantification of A2 was performed in the ng/ml range, analysis by ELISA suggested that a limit of 0.1ng/ml of A2 is approximate to 1 pathogen per ml and the sensing system shows the potential to deliver a similar level of quantification. Significant reduction in assay complexity as further enzyme linked enhancement is not required when applying a plasmonic methodology to an immunoassay. The basic instrumentation required for a portable device and potential dual optical readout where both plasmonic and photoluminescent response are assessed and investigated including consideration of the application of the device to testing where non-literate communication of results is considered and issues of performance are addressed.
- Published
- 2012
- Full Text
- View/download PDF
13. Recombinant Antigen-Based Enzyme-Linked Immunosorbent Assay for Diagnosis of Baylisascaris procyonisLarva Migrans
- Author
-
Dangoudoubiyam, Sriveny, Vemulapalli, Ramesh, Ndao, Momar, and Kazacos, Kevin R.
- Abstract
ABSTRACTBaylisascarislarva migrans is an important zoonotic disease caused by Baylisascaris procyonis, the raccoon roundworm, and is being increasingly considered in the differential diagnosis of eosinophilic meningoencephalitis in children and young adults. Although a B. procyonisexcretory-secretory (BPES) antigen-based enzyme-linked immunosorbent assay (ELISA) and a Western blot assay are useful in the immunodiagnosis of this infection, cross-reactivity remains a major problem. Recently, a recombinant B. procyonisantigen, BpRAG1, was reported for use in the development of improved serological assays for the diagnosis of Baylisascarislarva migrans. In this study, we tested a total of 384 human patient serum samples in a BpRAG1 ELISA, including samples from 20 patients with clinical Baylisascarislarva migrans, 137 patients with other parasitic infections (8 helminth and 4 protozoan), and 227 individuals with unknown/suspected parasitic infections. A sensitivity of 85% and a specificity of 86.9% were observed with the BpRAG1 ELISA, compared to only 39.4% specificity with the BPES ELISA. In addition, the BpRAG1 ELISA had a low degree of cross-reactivity with antibodies to Toxocarainfection (25%), while the BPES antigen showed 90.6% cross-reactivity. Based on these results, the BpRAG1 antigen has a high degree of sensitivity and specificity and should be very useful and reliable in the diagnosis and seroepidemiology of Baylisascarislarva migrans by ELISA.
- Published
- 2011
- Full Text
- View/download PDF
14. Identification of Novel Diagnostic Serum Biomarkers for Chagas' Disease in Asymptomatic Subjects by Mass Spectrometric Profiling
- Author
-
Ndao, Momar, Spithill, Terry W., Caffrey, Rebecca, Li, Hongshan, Podust, Vladimir N., Perichon, Regis, Santamaria, Cynthia, Ache, Alberto, Duncan, Mark, Powell, Malcolm R., and Ward, Brian J.
- Abstract
ABSTRACTMore than 10 million people are thought to be infected with Trypanosoma cruzi, primarily in the Americas. The clinical manifestations of Chagas' disease (CD) are variable, but most subjects remain asymptomatic for decades. Only 15 to 30% eventually develop terminal complications. All current diagnostic tests have limitations. New approaches are needed for blood bank screening as well as for improved diagnosis and prognosis. Sera from subjects with asymptomatic CD (n= 131) were compared to those from uninfected controls (n= 164) and subjects with other parasitic diseases (n= 140), using protein array mass spectrometry. To identify biomarkers associated with CD, sera were fractionated by anion-exchange chromatography and bound to two commercial ProteinChip array chemistries: WCX2 and IMAC3. Multiple candidate biomarkers were found in CD sera (3 to 75.4 kDa). Algorithms employing 3 to 5 of these biomarkers achieved up to 100% sensitivity and 98% specificity for CD. The biomarkers most useful for diagnosis were identified and validated. These included MIP1 alpha, C3a anaphylatoxin, and unusually truncated forms of fibronectin, apolipoprotein A1 (ApoA1), and C3. An antipeptide antiserum against the 28.9-kDa C terminus of the fibronectin fragment achieved good specificity (90%) for CD in a Western blot format. We identified full-length ApoA1 (28.1 kDa), the major structural and functional protein component of high-density lipoprotein (HDL), as an important negative biomarker for CD, and relatively little full-length ApoA1 was detected in CD sera. This work provides proof of principle that both platform-dependent (i.e., mass spectrometry-based) and platform-independent (i.e., Western blot) tests can be generated using high-throughput mass profiling.
- Published
- 2010
- Full Text
- View/download PDF
15. Multiplexed Real-Time PCR Assay for Discrimination of PlasmodiumSpecies with Improved Sensitivity for Mixed Infections
- Author
-
Shokoples, Sandra E., Ndao, Momar, Kowalewska-Grochowska, Kinga, and Yanow, Stephanie K.
- Abstract
ABSTRACTThe implementation of real-time PCR for the diagnosis of malaria has been hampered by poor sensitivity for the detection of mixed infections. We have optimized a method that enhances the sensitivity of detection of minor species in mixed infections within a single multiplex reaction. Our assay uses species-specific forward primers in combination with a conserved reverse primer and largely overcomes primer competition for the minor species DNA. With a blind panel of clinical samples, we successfully identified the species in 13/16 mixed infections. This assay was further validated with 91 blood samples and demonstrated a specificity and sensitivity for single infections of 100% compared with nested PCR as the “gold standard.” This test has been implemented for routine confirmation of malaria species in Alberta, Canada. In comparison with species identification by microscopy, the real-time PCR test demonstrated greater sensitivity for the identification of species causing low-level and mixed infections and for the discrimination of Plasmodiumspecies other than Plasmodium falciparum. Our experience supports a role for real-time PCR in the identification of malarial species in conjunction with microscopy.
- Published
- 2009
- Full Text
- View/download PDF
16. Purified Excreted-Secreted Antigens from Trypanosoma cruziTrypomastigotes as Tools for Diagnosis of Chagas' Disease
- Author
-
Berrizbeitia, Mariolga, Ndao, Momar, Bubis, Jose´, Gottschalk, Marcelo, Ache´, Alberto, Lacouture, Sonia, Medina, Mehudy, and Ward, Brian J.
- Abstract
ABSTRACTThere is currently no “gold standard” test for the diagnosis of late-stage Chagas' disease. As a result, protection of the blood supply in areas where Chagas' disease is endemic remains problematic. A panel of 709 serum samples from subjects with confirmed Chagas' disease (n= 195), healthy controls (n= 400), and patients with other parasitic diseases (n= 114) was used to assess enzyme-linked immunosorbent assays (ELISAs) based on a concentrated extract of excretory-secretory antigens from either Brazil or Tulahuen strain Trypanosoma cruzitrypomastigotes (total trypomastigote excretory-secretory antigens [TESAs]). The total TESA-based assays had excellent overall sensitivity (100%) and specificity (>94%), except for cross-reactivity with Leishmania-infected sera. In an attempt to increase the specificity of the assay, immunoaffinity chromatography was used to purify the TESA proteins (TESAIAproteins). By Western blotting, a series of polypeptide bands with molecular masses ranging from 60 to 220 kDa were recognized by pooled sera positive for Chagas' disease. An ELISA based on TESAIAproteins had a slightly lower sensitivity (98.6%) but an improved specificity (100%) compared to the sensitivity and specificity of the total TESA protein-based ELISAs. A 60-kDa polypeptide was identified as a major contributor to the cross-reactivity with Leishmania. These data suggest the need for field validation studies of TESA- and TESAIA-based assays in regions where Chagas' disease is endemic.
- Published
- 2006
- Full Text
- View/download PDF
17. Purified Excreted-Secreted Antigens from Trypanosoma cruzi Trypomastigotes as Tools for Diagnosis of Chagas' Disease
- Author
-
Berrizbeitia, Mariolga, Ndao, Momar, Bubis, José, Gottschalk, Marcelo, Aché, Alberto, Lacouture, Sonia, Medina, Mehudy, and Ward, Brian J.
- Abstract
There is currently no "gold standard" test for the diagnosis of late-stage Chagas' disease. As a result, protection of the blood supply in areas where Chagas' disease is endemic remains problematic. A panel of 709 serum samples from subjects with confirmed Chagas' disease (n = 195), healthy controls (n = 400), and patients with other parasitic diseases (n = 114) was used to assess enzyme-linked immunosorbent assays (ELISAs) based on a concentrated extract of excretory-secretory antigens from either Brazil or Tulahuen strain Trypanosoma cruzi trypomastigotes (total trypomastigote excretory-secretory antigens [TESAs]). The total TESA-based assays had excellent overall sensitivity (100%) and specificity (>94%), except for cross-reactivity with Leishmania-infected sera. In an attempt to increase the specificity of the assay, immunoaffinity chromatography was used to purify the TESA proteins (TESAIA proteins). By Western blotting, a series of polypeptide bands with molecular masses ranging from 60 to 220 kDa were recognized by pooled sera positive for Chagas' disease. An ELISA based on TESAIA proteins had a slightly lower sensitivity (98.6%) but an improved specificity (100%) compared to the sensitivity and specificity of the total TESA protein-based ELISAs. A 60-kDa polypeptide was identified as a major contributor to the cross-reactivity with LEISHMANIA: These data suggest the need for field validation studies of TESA- and TESAIA-based assays in regions where Chagas' disease is endemic.
- Published
- 2006
18. Malaria epidemic in Quebec: diagnosis and response to imported malaria
- Author
-
Ndao, Momar, Bandyayera, Etienne, Kokoskin, Evelyne, Diemert, David, Gyorkos, Theresa W., MacLean, J. Dick, John, Ron St., and Ward, Brian J.
- Published
- 2005
19. Comparison of Blood Smear, Antigen Detection, and Nested-PCR Methods for Screening Refugees from Regions Where Malaria Is Endemic after a Malaria Outbreak in Quebec, Canada
- Author
-
Ndao, Momar, Bandyayera, Etienne, Kokoskin, Evelyne, Gyorkos, Theresa W., MacLean, J. Dick, and Ward, Brian J.
- Abstract
ABSTRACTThe importation of malaria into a region where it is not endemic raises many concerns, including the timely delivery of appropriate care, safety of the blood supply, and the risk of autochthonous transmission. There is presently no consensus on the best way to screen mobile populations for malaria. Between August 2000 and March 2001, 535 refugees arrived in Quebec, Canada, from Tanzanian camps. Within 4 weeks of resettlement of the first group of 224, the McGill University Centre for Tropical Diseases noted an outbreak of malaria across the province (15 cases over a 3-week period). This group (group 1) was traced and screened for malaria between 3 and 4 months after arrival in Canada. Subsequent groups of 106 and 205 refugees were screened immediately upon arrival in Canada (group 2) and immediately prior to their departure from refugee camps (group 3), respectively. A single EDTA-blood sample was obtained from 521 refugees for testing by thick and thin blood smears (groups 1 and 2), antigen detection (ICT Malaria Pf and OptiMAL; group 1 only), and nested PCR (all groups). Overall, 98 of 521 refugees were found to be infected (18.8%). The vast majority of infections (81 of 98) were caused by Plasmodium falciparumalone. Using PCR as the “gold standard,” both microscopy (sensitivity, 50%; specificity, 100%) and antigen detection (ICT sensitivity, 37.5%; ICT specificity, 100%; OptiMAL sensitivity, 29.1%; OptiMAL specificity, 95.6%) performed poorly. None of the PCR-positive subjects were symptomatic at the time of testing, and only two had recently had symptoms compatible with malaria (with or without diagnosis and treatment). Active surveillance of migrants from regions of intense malaria transmission can reduce the risk of morbidity in the migrant population and mitigate against transmission to the host population. Our data demonstrate that PCR is, by far, the most powerful tool for such surveillance.
- Published
- 2004
- Full Text
- View/download PDF
20. Development and Comparison of Enzyme Immunoassays for Diagnosis of Chagas' Disease Using Fixed Forms of Trypanosoma cruzi(Epimastigotes, Amastigotes, and Trypomastigotes) and Assessment of Antigen Stability for the Three Assays
- Author
-
Berrizbietia, Mariolga, Ndao, Momar, Gottschalk, Marcelo, Ache´, Alberto, Va´squez, Fabio, Lacouture, Sonia, Medina, Mehudy, and Ward, Brian J.
- Abstract
ABSTRACTThree enzyme immunoassays (EIAs) for diagnosis of Chagas' disease were developed with fixed forms of Trypanosoma cruziusing a panel of 435 sera from the following groups: Venezuelan subjects positive by immunofluorescence (n= 70), Venezuelan healthy controls (n= 85), healthy Canadians (n= 166), and subjects with other parasitic diseases (n= 114). All assays achieved 100% sensitivity and reasonable specificity for amastigotes (97.6%), epimastigotes (98.3%), and trypomastigotes (99.3%). The fixed-trypomastigote assay was stable over 4 months at 4°C and room temperature. These data suggest that a fixed-trypomastigote EIA may be a suitable candidate for blood bank screening.
- Published
- 2004
- Full Text
- View/download PDF
21. Identification of broadly conserved cross-species protective Leishmaniaantigen and its responding CD4+T cells
- Author
-
Mou, Zhirong, Li, Jintao, Boussoffara, Thouraya, Kishi, Hiroyuki, Hamana, Hiroshi, Ezzati, Peyman, Hu, Chuanmin, Yi, Weijing, Liu, Dong, Khadem, Forough, Okwor, Ifeoma, Jia, Ping, Shitaoka, Kiyomi, Wang, Shufeng, Ndao, Momar, Petersen, Christine, Chen, Jianping, Rafati, Sima, Louzir, Hechmi, Muraguchi, Atsushi, Wilkins, John A., and Uzonna, Jude E.
- Abstract
A Leishmaniaprotein vaccine elicited immune responses and mediated strong cross-species protection.
- Published
- 2015
- Full Text
- View/download PDF
22. A Family Cluster of Chagas Disease Detected through Selective Screening of Blood Donors: A Case Report and Brief Review
- Author
-
Mongeau-Martin, Guillaume, Ndao, Momar, Libman, Michael, Delage, Gilles, and J Ward, Brian
- Abstract
Chagas disease (CD) is a protozoan infection caused by Trypanosoma cruzi, which is transmitted by triatomine insect vectors in parts of Latin America. In a nonendemic country, such as Canada, spread can still occur via vertical transmission, and infected blood or organ donations. The Canadian Blood Services and Héma-Québec have both implemented selective screening of blood donors for CD based on risk factors. In 2011, Héma-Québec identified two seropositive ‘at-risk’ Chilean siblings who had donated blood in Montreal, Quebec. They were referred to the JD MacLean Centre for Tropical Diseases (Montreal, Quebec) for confirmatory testing (T cruzi excreted-secreted antigen ELISA, polymerase chain reaction and/or radioimmunoprecipitation assay) and follow-up. Screening of the rest of the family revealed two other seropositive family members (the mother and sister). While their geographical history in Chile suggests vectorial transmission, this family cluster of CD raises the possibility of vertical transmission. Congenital infection should always be considered among CD-positive mothers and pregnant women. With blood donor screening, Canadian physicians will increasingly see patients with CD and should know how to manage them appropriately. In addition to the case presentation, the authors review the transmission, screening and clinical management of CD in a nonendemic context.
- Published
- 2015
- Full Text
- View/download PDF
23. Zoonotic Infections in Communities of the James Bay Cree Territory: An Overview of Seroprevalence
- Author
-
Sampasa-Kanyinga, Hugues, Lévesque, Benoit, Anassour-Laouan-Sidi, Elhadji, Côté, Suzanne, Serhir, Bouchra, J Ward, Brian, D Libman, Michael, A Drebot, Michael, Makowski, Kai, Dimitrova, Kristina, Ndao, Momar, and Dewailly, Éric
- Abstract
The Cree communities of James Bay are at risk for contracting infectious diseases transmitted by wildlife. Data from serological testing for a range of zoonotic infections performed in the general population (six communities), or trappers and their spouses (one community), were abstracted from four population-based studies conducted in Cree territory (Quebec) between 2005 and 2009. Evidence of exposure to Trichinella species, Toxoplasma gondii, Toxocara canis, Echinococcus granulosus, Leptospira species, Coxiella burnetii and Francisella tularensis was verified in all communities, whereas antibodies against Sin Nombre virus and California serogroup viruses (Jamestown Canyon and snowshoe hare viruses) were evaluated in three and six communities, respectively. Seroprevalence varied widely among communities: snowshoe hare virus (1% to 42%), F tularensis (14% to 37%), Leptospira species (10% to 27%), Jamestown Canyon virus (9% to 24%), C burnetii (0% to 18%), T gondii (4% to 12%), T canis (0% to 10%), E granulosus (0% to 4%) and Trichinella species (0% to 1%). No subject had serological evidence of Sin Nombre virus exposure. These data suggest that large proportions of the Cree population have been exposed to at least one of the targeted zoonotic agents. The Cree population, particularly those most heavily exposed to fauna, as well as the medical staff living in these regions, should be aware of these diseases. Greater awareness would not only help to decrease exposures but would also increase the chance of appropriate diagnostic testing.
- Published
- 2013
- Full Text
- View/download PDF
24. A Case of Vertical Transmission of Chagas Disease Contracted via Blood Transfusion in Canada
- Author
-
A Fearon, Margaret, Scalia, Vito, Huang, Mary, Dines, Irene, Ndao, Momar, and Lagacé-Wiens, Philippe
- Abstract
Chagas disease is caused by the protozoan parasite Trypanosoma cruzi and is endemic in many countries in Latin America, where infected bugs of the Triatominea subfamily carry the parasite in the gut and transmit it to humans through fecal contamination of a bite. However, vertical transmission and transmission through blood transfusion and organ transplantation is well documented. Increasing immigration from endemic countries to North America has prompted blood operators, including Canadian Blood Services and Hema Quebec, to initiate blood donor testing for Chagas antibody. In the present report, an unusual case of vertical transmission from a mother, most likely infected through blood transfusion, and detected as part of a concurrent seroprevalence study in blood donors is described.
- Published
- 2013
- Full Text
- View/download PDF
25. P-123
- Author
-
Sampasa-Kanyinga, Hugues, Lévesque, Benoit, Anassour-Laouan-Sidi, Elhadji, Côté, Suzanne, Serhir, Bouchra, Ward, Brian J, Libman, Michael D, Drebot, Michael A, Ndao, Momar, and Dewailly, Éric
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.